Suppr超能文献

镰状细胞病合作研究中的静脉血栓栓塞发生率。

Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.

作者信息

Naik R P, Streiff M B, Haywood C, Segal J B, Lanzkron S

机构信息

Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.

出版信息

J Thromb Haemost. 2014 Dec;12(12):2010-6. doi: 10.1111/jth.12744. Epub 2014 Oct 18.

Abstract

BACKGROUND

Venous thromboembolism (VTE) has been recently recognized as a complication of sickle cell disease (SCD); however, the incidence of VTE in SCD is unknown.

OBJECTIVES

The primary objective of this study was to determine the incidence of first VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), among SCD patients age ≥ 15 years. We also evaluated genotypic differences in VTE risk and determined the relationship between VTE and mortality.

PATIENTS/METHODS: In this retrospective cohort study, we used data from the Cooperative Study of Sickle Cell Disease (CSSCD) to calculate incidence rates for first VTE. We used Cox proportional hazard models to estimate hazard ratios (HRs) for time to VTE by genotype and time to death by VTE status.

RESULTS

We included 1523 SCD patients aged ≥ 15 years with 8862 years of follow-up in this analysis. The incidence rate for first VTE was 5.2 events/1000 person-years (95% confidence interval [CI] 3.8-6.9) with a cumulative incidence of 11.3% (95% CI 8.3-15.3) by age 40 years. Individuals with the SS/Sβ(0) -thalassemia genotype had the highest rate of VTE (7.6 events/1000 person-years [95% CI 5.3-10.6]). The incidence of PE exceeded that of isolated DVT (3.6 [95% CI 2.5-5.1] events/1000 person-years vs. 1.6 [95% CI 0.9-2.7] events/1000 person-years), although this difference was not statistically significant. SCD patients with VTE had a higher mortality rate (adjusted HR 2.32 [95% CI 1.20-4.46]) than those without VTE.

CONCLUSIONS

Patients with SCD are at substantial risk for VTE, and individuals with VTE are at higher risk of death than those without VTE.

摘要

背景

静脉血栓栓塞症(VTE)最近被认为是镰状细胞病(SCD)的一种并发症;然而,SCD中VTE的发病率尚不清楚。

目的

本研究的主要目的是确定年龄≥15岁的SCD患者中首次发生VTE(包括肺栓塞(PE)和深静脉血栓形成(DVT))的发病率。我们还评估了VTE风险的基因型差异,并确定了VTE与死亡率之间的关系。

患者/方法:在这项回顾性队列研究中,我们使用镰状细胞病合作研究(CSSCD)的数据来计算首次VTE的发病率。我们使用Cox比例风险模型来估计按基因型计算的VTE发生时间和按VTE状态计算的死亡时间的风险比(HR)。

结果

在本次分析中,我们纳入了1523名年龄≥15岁的SCD患者,随访时间为8862人年。首次VTE的发病率为5.2例/1000人年(95%置信区间[CI]3.8 - 6.9),到40岁时累积发病率为11.3%(95%CI 8.3 - 15.3)。SS/Sβ(0) -地中海贫血基因型的个体VTE发生率最高(7.6例/1000人年[95%CI 5.3 - 10.6])。PE的发病率超过了孤立性DVT的发病率(3.6[95%CI 2.5 - 5.1]例/1000人年对1.6[95%CI 0.9 - 2.7]例/1000人年),尽管这种差异无统计学意义。患有VTE的SCD患者的死亡率(调整后HR 2.32[95%CI 1.20 - 4.46])高于未患VTE的患者。

结论

SCD患者发生VTE的风险很大,患有VTE的个体比未患VTE的个体死亡风险更高。

相似文献

1
Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.
J Thromb Haemost. 2014 Dec;12(12):2010-6. doi: 10.1111/jth.12744. Epub 2014 Oct 18.
2
Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.
Br J Haematol. 2017 Jul;178(2):319-326. doi: 10.1111/bjh.14655. Epub 2017 Apr 3.
3
High incidence of venous thromboembolism recurrence in patients with sickle cell disease.
Am J Hematol. 2019 Aug;94(8):862-870. doi: 10.1002/ajh.25508. Epub 2019 Jun 12.
4
Incidence of venous thromboembolism in patients with sickle cell disease undergoing noncardiovascular surgery.
J Vasc Surg Venous Lymphat Disord. 2023 May;11(3):543-552. doi: 10.1016/j.jvsv.2022.11.004. Epub 2022 Dec 24.
5
Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromsø Study.
J Thromb Haemost. 2016 Jun;14(6):1183-91. doi: 10.1111/jth.13329. Epub 2016 May 10.
6
Long-term risk of venous thromboembolism recurrence after isolated superficial vein thrombosis.
J Thromb Haemost. 2017 Jun;15(6):1123-1131. doi: 10.1111/jth.13679. Epub 2017 May 5.
7
Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study.
J Pediatr. 2018 Jun;197:186-190.e1. doi: 10.1016/j.jpeds.2018.01.073. Epub 2018 Mar 28.
9
Risk and complications of venous thromboembolism in dialysis patients.
Nephrol Dial Transplant. 2018 May 1;33(5):874-880. doi: 10.1093/ndt/gfx212.
10
The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
J Thromb Haemost. 2016 Dec;14(12):2402-2409. doi: 10.1111/jth.13524. Epub 2016 Nov 19.

引用本文的文献

2
Ischemic Stroke as the Initial Presentation of Sickle Beta Thalassemia in an Adolescent: A Case Report.
Cureus. 2025 May 16;17(5):e84254. doi: 10.7759/cureus.84254. eCollection 2025 May.
3
Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):644-651. doi: 10.1182/hematology.2024000591.
4
Postpartum Acquired Hemophilia A.
J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):85-88. doi: 10.55729/2000-9666.1382. eCollection 2024.
5
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.
MMWR Recomm Rep. 2024 Aug 8;73(4):1-126. doi: 10.15585/mmwr.rr7304a1.
6
Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study.
Res Pract Thromb Haemost. 2024 Jun 10;8(4):102471. doi: 10.1016/j.rpth.2024.102471. eCollection 2024 May.
7
Diagnosis and management of chronic thromboembolic pulmonary hypertension (CTEPH) in sickle cell disease: A review.
Pulm Circ. 2024 May 27;14(2):e12362. doi: 10.1002/pul2.12362. eCollection 2024 Apr.
10

本文引用的文献

1
Hemostatic abnormalities in sickle cell disease.
Curr Opin Hematol. 2013 Sep;20(5):472-7. doi: 10.1097/MOH.0b013e328363442f.
3
Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.
J Thromb Thrombolysis. 2013 Apr;35(3):352-8. doi: 10.1007/s11239-013-0895-y.
4
Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum.
Blood. 2012 Aug 2;120(5):933-46. doi: 10.1182/blood-2012-02-407551. Epub 2012 Apr 10.
5
Pulmonary embolism in sickle cell disease: a case-control study.
J Thromb Haemost. 2012 May;10(5):760-6. doi: 10.1111/j.1538-7836.2012.04697.x.
6
Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease.
Am J Respir Crit Care Med. 2011 Nov 1;184(9):1022-9. doi: 10.1164/rccm.201105-0783OC.
8
9
Hypercoagulability in sickle cell disease: new approaches to an old problem.
Hematology Am Soc Hematol Educ Program. 2007:91-6. doi: 10.1182/asheducation-2007.1.91.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验